| TRADING CENTER |
| Genzyme's Termeer: Worst Biotech CEO of '09 - at TheStreet.com | |
| Osiris Posts Loss - Analyst Blog - Zacks.com | |
| Osiris Therapeutics Reports Third Quarter 2009 Financial Results - Business Wire | |
| Osiris Therapeutics Achieves $15 Million Milestone Payment - Business Wire | |
| Integrity Media: Stem Cell Report Released - GlobeNewswire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 55.38 | -0.68 / -1.21% | 10.59 |
| GILD | Gilead Sciences Inc | 46.39 | -0.13 / -0.28% | 17.91 |
| CELG | Celgene Corporation | 54.91 | 0.36 / 0.66% | 66.16 |
| 2008 Revenue: | $10.0 M | Headquarters: Columbia, MD |
| Employees: | 163 | CEO: Dr. C. Randal Mills, Ph.D. |
| Net Income: | $-33,492,000.0 | Industry: Biotechnology |
| Market Cap: | $215.3 M | Website: www.osiristx.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| OSIR | 6.57 | +0.09 / +1.39% | 6.48 | 6.64 | 6.49 | Profile Chart News |